Investors - Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Our websites

 
 

Middle area:

Cash flow

The following tables present simplified consolidated cash flows. Detailed tables with consolidated cash flow statements are available in the latest annual reports on Form 20-F and half-year financial reports.
 

Net Debt in 2012

In 2012, net cash generated by operating activities after changes in working capital, after capital expenditures (€1,402 million), and before restructuring costs was €7,375 million, a decrease of 11.8% compared to 2011. This amount covered the dividend paid by Sanofi (€3,487 million), repurchase of shares (€823 million), acquisitions and partnerships (€538 million) and restructuring costs (€791 million). In 2012, disposals accounted for €358 million (especially the stake in Yves Rocher). As a consequence, net debt decreased from €10,859 million at December 31, 2011 to €7,719 million at the end of 2012 (amount net of €6,381 million cash and cash equivalents).

  
Top of page

Change in net debt 2012 / 2011

Change in net debt 2012 / 2011
Millions of eurosFY 2012FY 2011
Business net income8,1798,795
Depreciation, amortization and impairment of property, plant and equipment and intangible assets1,2781,156
Net gains and losses on disposals of non-current assets, net of tax(86)(52)
Other non cash items(58)579
Operating cash flow before changes in working capital19,31310,478
Changes in working capital1(536)(476)
Acquisitions of property, plant and equipment and software(1,402)(1,644)
Free cash flow17,3758,358
Acquisitions of intangibles, excluding software(210)(138)
Acquisitions of investments, including assumed debt2(328)(14,079)
Restructuring costs paid(791)(707)
Proceeds from disposals of property, plant and equipment, intangibles, and other non-current assets, net of tax358359
Issuance of Sanofi shares64570
Dividends paid to Sanofi shareholders(3,487)(1,372)
Acquisition of treasury shares(823)(1,074)
Disposals of treasury shares, net of tax13
Other items3400(702)
Change in net debt3,140(9,282)

(1) Excluding restructuring costs
(2) In 2011: (13,528) M€ related to Genzyme acquisition
(3) of which : foreign exchange effect on net debt +281M€ in 2012 and (754) M€ in 2011

  
 

Further information on consolidated statements of cash flows is available in the Annual report on Form 20-F 2012:

  
Top of page

Change in net debt 2011 / 2010

Change in net debt 2011 / 2010
Millions of eurosFY 2011FY 2010
Business net income8,7959,215
Depreciation, amortization and impairment of property, plant and equipment and intangibles1,1561,080
Net gain/loss on disposals of non-current assets, net of tax(52)(111)
Other non cash items579550
Operating cash flow before changes in working capital*10,47810,734
Changes in working capital*(476)57
Acquisitions of property, plant and equipment and software(1,644)(1,349)
Free cash flow*8,3589,442
Acquisitions of intangibles, excluding software(138)(313)
Acquisitions of investments, including assumed debt**(14,079)(2,121)
Restructuring costs paid(707)(892)
Proceeds from disposals of property, plant and equipment, intangibles, and other non-current assets (net of tax)359111
Issuance of Sanofi shares7018
Dividends paid to Sanofi shareholders(1,372)(3,131)
Acquisition of treasury shares(1,074)(321)
Disposals of treasury shares, net of tax357
Other items***(702)(299)
Change in net debt((9,282)(2,551)

* Excluding restructuring costs.
** In 2011: (€13,528 million) related to Genzyme acquisition
*** In 2011: of which foreign exchange effect on net debt (€754 million)

  

2011 key figures

  • Cash flow from operations: €10,002 million
  • Capital expenditure: €1,644 million
  • Sanofi dividend: €1,372 million
  • Restructuring costs: €707 million
  • Acquisitions and partnerships: €14,079 million
  • Repurchase of own shares: €1,074 million
  • Net debt at December 31, 2011: €10,859 million
    (debt of €14,983 million, net of €4,124 million cash and cash equivalents) 
 

Further information on consolidated statements of cash flows is available in the Annual report on Form 20-F 2011:

  
Top of page

Change in net debt 2010 / 2009

Change in net debt 2010 / 2009
€ million20102009
Business net income9,2158,629
Net income from the held-for-exchange Merial business(418)(241)
Net dividends from the held-for-exchange Merial business497179
Depreciation, amortization and impairment of property, plant and equipment and intangibles1,003964
Net gain/loss on disposals of non-current assets, net of tax(111)(25)
Other items548668
Operating cash flow before changes in working capital*10,73410,174
Changes in working capital*(57)(1,283)
Acquisitions of property, plant and equipment and software(1,261)(1,460)
Free cash flow*9,4167,431
Acquisitions of intangibles, excluding software(312)(325)
Acquisitions of investments, including assumed debt(2 121)(6 334)
Restructuring costs paid(892)(376)
Proceeds from disposals of property, plant and equipment, intangibles, and other non-current assets (net of tax)10685
Issuance of sanofi-aventis shares18142
Dividends paid to sanofi-aventis shareholders(3,131)(2,872)
Acquisition of treasury shares(321)
Disposals of treasury shares, net of tax5726
Other items(269)(103)
Change in net debt**2,551(2,326)

2010 key figures

  • Cash flow from operations: €10,677 million
  • Capital expenditure: €1,261 million
  • Sanofi-aventis dividend: €3,131 million
  • Restructuring costs: €892 million
  • Acquisitions: €2,121 million
  • Alliances: €312 million
  • Repurchase of own shares: €321 million
  • Net debt at December 31, 2010: €1,577 million
    (debt of €8,042 million, net cash of €6,465 million)
 

Further information on consolidated statements of cash flows is available in the Annual report on Form 20-F 2010:

  
Top of page

Right area:

Stock Market

Income Statements

Merial

 

Historical Consolidated Net Sales

 

Business Net Income

   

Your services

 

Further information

Event

 

Publications

 

SEC Filings

 

Tools menu:

© Sanofi 2004-2013 - All rights reserved - Update: March 08, 2013

Site complies with W3C WCAG 2.0 (new window, in english)